0000000000385648

AUTHOR

Andreas Kuemmel

showing 6 related works from this author

Humoral immune responses of lung cancer patients against the Transmembrane Phosphatase with TEnsin homology (TPTE).

2015

Abstract Objective The cancer/testis (C/T) antigen Transmembrane Phosphatase with TEnsin homology (TPTE) is aberrantly expressed in many tumors including lung cancer. In the present study, we analyzed TPTE-auto-antibodies in lung cancer patients. Methods Using a crude-lysate ELISA, we analyzed a large cohort of 307 sera from lung cancer patients and 47 healthy donors for TPTE-specific autoantibodies. Sero-reactivity was correlated with clinical parameters and patients’ survival. Results TPTE-specific antibodies were detected in 41 of 307 (13.4%) sera from lung cancer patients. Based on an optimal cut-off value calculated by ROC curve analysis sensitivity for diagnosing lung cancer was 52% a…

Pulmonary and Respiratory MedicineOncologyMaleCancer Researchmedicine.medical_specialtyPathologyLung NeoplasmsAntibodies NeoplasmImmune systemAntigenAntigens NeoplasmInternal medicineTensinsmedicineTensinHumansLung cancerAutoantibodiesbiologybusiness.industryMicrofilament ProteinsAutoantibodyPTEN PhosphohydrolaseMembrane ProteinsMiddle Agedmedicine.diseasePrognosisImmunity HumoralOncologybiology.proteinCancer/testis antigensFemaleNY-ESO-1AntibodybusinessLung cancer (Amsterdam, Netherlands)
researchProduct

The prognostic impact of blood group-related antigen Lewis Y and the ABH blood groups in resected non-small cell lung cancer.

2007

The blood group antigen Lewis Y is expressed on epithelial tumors of the respiratory, digestive and reproductive system. Despite being regarded as an attractive target for immunotherapy, its function is still not well defined and its prognostic value remains a subject of discussion. Eighty-three paraffin-embedded tissue sections of non-small cell lung cancer (NSCLC) patients in stage I-IIIa, who underwent surgical resection of the primary tumor (73% male; 43% adenocarcinoma), were stained with a new, highly specific monoclonal antibody against Lewis Y (clone A70-C/C8). A positive Lewis Y expression was observed in 51% of patients; adenocarcinomas were favorably stained (67%). Multivariate a…

MalePathologymedicine.medical_specialtyLung Neoplasmsmedicine.drug_classmedicine.medical_treatmentMonoclonal antibodyABO Blood-Group SystemImmunoenzyme TechniquesLewis Blood Group AntigensAntigenAntigens NeoplasmCarcinoma Non-Small-Cell LungmedicineCarcinomaBiomarkers TumorHumansReproductive systemRespiratory systemLung cancerSurvival rateNeoplasm Stagingbusiness.industryGeneral MedicineImmunotherapyMiddle Agedmedicine.diseasePrognosisSurvival RatebusinessFollow-Up StudiesTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
researchProduct

Bcl-2, Bcl-xl, and pp32/PHAPI in resected non-small-cell lung cancer patients

2009

Einleitung: Fur viele Tumorarten ist der Einfluss des Apoptosesignalweges auf die Prognose der Tumorerkrankung beschrieben worden. So konnte fur die antiapoptotischen Proteine wie Bcl-2 und Bcl-xL gezeigt werden, dass sie den mitochondrialen Selbstzerstorungsmechanismus der Zellen herunterregulieren konnen. Fur nicht-kleinzellige Lungenkarzinomen (NSCLC) hingegen existieren widerspruchliche Angaben in der wissenschaftlichen Literatur in Bezug auf die prognostische Wertigkeit apoptotischer und insbesondere antiapoptotischer Faktoren. Ein weiterer wichtiger Faktor im genannten Mechanismus, welches NSCLC fur apoptotische Stimuli sensibilisieren soll, ist das Protein pp32/PHAPI. Fur bereits che…

Pulmonary and Respiratory MedicineBcl 2 bcl xlbusiness.industryCancer researchMedicineNon small cellbusinessLung cancermedicine.diseaseMolecular biologyPneumologie
researchProduct

Catumaxomab: a bispecific trifunctional antibody.

2009

The trifunctional bispecific monoclonal antibody catumaxomab has two binding specificities directed at epithelial cell adhesion molecule (EpCAM) and the T-cell antigen CD3. With its Fc-fragment, catumaxomab additionally binds accessory cells such as dendritic cells, macrophages and natural killer cells. The trifunctional approach thus leads to unrestricted but specific killing of epithelial tumor cells by major histocompatibility complex without the need for preactivation or external costimulation. The tumor-associated antigen EpCAM is strongly expressed in carcinomas of various origins including colon, rectum, ovarian, gastric, esophagus, lung, pancreas, breast and head and neck. Expressio…

CD3CatumaxomabAntineoplastic AgentsMajor histocompatibility complexchemistry.chemical_compoundAntigenAntigens NeoplasmNeoplasmsAntibodies BispecificMedicineAnimalsHumansPharmacology (medical)PharmacologybiologyBispecific monoclonal antibodybusiness.industryDrug Administration RoutesModels ImmunologicalEpithelial cell adhesion moleculeGeneral MedicineTrifunctional antibodychemistrybiology.proteinCancer researchAntibodyDrug Screening Assays Antitumorbusinessmedicine.drugDrugs of today (Barcelona, Spain : 1998)
researchProduct

TA-MUC1 epitope in non-small cell lung cancer

2007

MUC1 (CD227), an established tumor marker, is expressed on glandular epithelia and on epithelial tumors. Tumor MUC1 differs from normal MUC1 by modified glycan side chains. Recently, a novel carbohydrate-induced conformational tumor-associated MUC1 epitope (TA-MUC1) was described, whose clinical relevance in lung cancer is not known. Eighty-five paraffin embedded tissue sections of non-small cell lung cancer (NSCLC) patients (73% male; mean age 64+/-9 years) were stained with the monoclonal antibody PankoMab (against TA-MUC1) and compared with the established antibodies E29 and 214D4 regarding prognostic relevance. TA-MUC1 is virtually absent in bronchial epithelium. As shown by multivariat…

MalePulmonary and Respiratory MedicineCancer ResearchPathologymedicine.medical_specialtyLung Neoplasmsmedicine.drug_classMonoclonal antibodydigestive systemAntibodiesEpitopeEpitopesCarcinoma Non-Small-Cell LungCarcinomamedicineHumansskin and connective tissue diseasesLung cancerneoplasmsLymph nodeMUC1AgedTumor markerbiologybusiness.industryMucin-1Antibodies MonoclonalMiddle AgedPrognosismedicine.diseaseImmunohistochemistrybiological factorsdigestive system diseasesTreatment Outcomemedicine.anatomical_structureOncologyLymphatic Metastasisbiology.proteinFemaleAntibodybusinessLung Cancer
researchProduct

Blood group antigen A type 3 expression is a favorable prognostic factor in advanced NSCLC.

2015

Abstract Objectives Several blood group-related carbohydrate antigens are prognosis-relevant markers of tumor tissues. A type 3 (repetitive A) is a blood group antigen specific for A 1 erythrocytes. Its potential expression in tumor tissues has so far not been examined. Material and methods We have evaluated its expression in normal lung and in lung cancer using a novel antibody (A69-A/E8). For comparison an anti-A antibody specific to A types 1 and 2 was used, because its expression on lung cancer tissue has been previously reported to be of prognostic relevance. Resected tissue samples of 398 NSCLC patients were analyzed in immunohistochemistry using tissue microarrays. Results and conclu…

0301 basic medicinePulmonary and Respiratory MedicineOncologyMaleCancer Researchmedicine.medical_specialtyPathologyLung Neoplasms03 medical and health sciences0302 clinical medicineAntigenAntigens NeoplasmInternal medicineCarcinoma Non-Small-Cell LungmedicineBiomarkers TumorHumansLung cancerProspective cohort studyAgedTissue microarrayLungbiologyProportional hazards modelbusiness.industrymedicine.diseasePrognosisImmunohistochemistrySurvival Analysisrespiratory tract diseases030104 developmental biologymedicine.anatomical_structureOncologyTissue Array Analysis030220 oncology & carcinogenesisbiology.proteinBlood Group AntigensImmunohistochemistryFemaleAntibodybusinessLung cancer (Amsterdam, Netherlands)
researchProduct